The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis

Lande, Roberto; Botti, Elisabetta; Jandus, Camilla; Dojcinovic, Danijel; Fanelli, Giorgia; Conrad, Curdin; Chamilos, Georgios; Feldmeyer, Laurence; Marinari, Barbara; Chon, Susan Y.; Vence, Luis M.; Riccieri, Valeria; Guillaume, Phillippe; Navarini, Alexander A.; Romero, Pedro; Costanzo, Antonio; Piccolella, Enza; Gilliet, Michel; Frasca, Loredana

doi:10.1038/ncomms6621

Cited by 468 publications

(496 citation statements)

References 68 publications

(109 reference statements)

Supporting

Mentioning

464

Contrasting

Unclassified

Order By: Relevance

“…Although it has been thought that psoriasis is caused by an autoimmune mechanism,91 recent studies using mouse models suggest the involvement of innate immunity 92. High frequency of γδ T cells is detected in psoriasiform dermal lesions in mice induced by IMQ, and these cells produce IL‐17 through stimulation with IL‐23,23 indicating the innate immune nature of the disease.…”

Section: γδ17 Cells In Human Inflammatory Diseasesmentioning

confidence: 99%

“…In this report, however, V γ 9 + V δ 2 + cells were activated to produce cytokines from keratinocytes by the specific antigen, suggesting that recognition of specific antigens may be important for the development of psoriasis. Because Th17 cells94 and ILC3s95 as well as γδ 17 cells91 are also detected in the psoriatic skin, the involvement of autoimmunity and the main source of IL‐17 during the development of psoriasis still remain obscure in humans.…”

Section: γδ17 Cells In Human Inflammatory Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Interleukin‐17‐producing γδ T (γδ17) cells in inflammatory diseases

Akitsu

Iwakura

2018

Immunology

View full text Add to dashboard Cite

SummaryInterleukin‐17 (IL‐17) is a pro‐inflammatory cytokine and is involved in the development of many diseases. Recent studies have revealed that IL‐17‐producing γδ T cells (γδ17 cells) in addition to IL‐17‐producing CD4+ T cells [T helper type 17 (Th17) cells] are often the main producers of IL‐17 in mouse models of inflammatory diseases. γδ T cells are functionally committed during intra‐thymic differentiation. γδ thymocytes capable of producing IL‐17, which express the transcription factor retinoic‐acid‐receptor‐related orphan receptor γt and the signature cytokine receptor IL‐23R, leave the thymus, and produce IL‐17 rapidly by the stimulation with IL‐1β and IL‐23 in the periphery. Therefore, γδ17 cells play important roles in the early phase of host defence against pathogens and in inflammatory diseases. γδ T cells that can produce IL‐17 are also increased in the skin of patients with psoriasis and in peripheral blood of patients with ankylosing sclerosis. Indeed, the therapy targeting IL‐17 has been approved or is in clinical trials, and proved to be very efficient to treat psoriasis, psoriatic arthritis and ankylosing sclerosis. In this review, we discuss recent knowledge about the pathophysiological function of γδ17 cells in infection and inflammatory diseases and therapeutic advances targeting IL‐17.

show abstract

Section: γδ17 Cells In Human Inflammatory Diseasesmentioning

confidence: 99%

Section: γδ17 Cells In Human Inflammatory Diseasesmentioning

confidence: 99%

Interleukin‐17‐producing γδ T (γδ17) cells in inflammatory diseases

Akitsu

Iwakura

2018

Immunology

View full text Add to dashboard Cite

show abstract

“…Эти клетки вырабатывают широкий спектр цитокинов, кото-рые, действуя на кератиноциты и другие кожные рези-дентные клетки, индуцируют гиперпролиферацию эпи-дермиса, неоангиогенез и воспаление кожи в целом. Уни-кальное место в иммунопатогенезе псориаза занимают два аутоантигена: кателицидин (cathelicidin/LL-37) и ADAMTS-подобный белок 5 [25,26], презентация кото-рых ДК индуцирует синтез ИЛ23. В коже пациентов с псориазом отмечено увеличение содержания Th17-кле-ток, γδТ-клеток, ILC3-клеток, клеток -ЕК, тучных кле-ток, синтезирующих ИЛ17, ИЛ23, ИЛ22, ИЛ23Р и ФНОα [27].…”

Section: псориазunclassified

New Possibilities of Pharmacotherapy for Immunoinflammatory Rheumatic Diseases: A Focus on Inhibitors of Interleukin-17

Насонов¹

2017

rsp

View full text Add to dashboard Cite

“…It can occur at any age, although the majority of cases develop before the age of 50 years and it is uncommon in children. Psoriasis is considered to be an autoimmune disease, and the precise nature of the autoantigens triggering T-cell responses is being elucidated [2]. Psoriasis has a strong genetic component with the majority of the patients having relatives affected [1].…”

Section: Introductionmentioning

confidence: 99%

Systemic therapy of psoriasis in diabetic patients

Gisondi¹,

Perazzolli²,

Giglio³

et al. 2015

Glob Dermatol

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease affecting 2-3% of worldwide population. Moderate to severe psoriasis is frequently associated with metabolic disorders including diabetes, obesity, dyslipidaemia, metabolic syndrome and non-alcoholic fatty liver disease. In particular, the prevalence of diabetes in patients with psoriasis ranges from 5 to 54%. Most of the studies found that the prevalence of diabetes is higher in patients with moderate to severe psoriasis compared to mild disease. The association between psoriasis and diabetes could be explained considering several factors including a common genetic background, the high prevalence of metabolic risk factors for diabetes in patients with psoriasis as well as unhealthy life-styles such heavy drinking, over-eating and sedentary, which are common in patients with psoriasis. From a clinical prospective, the understanding of the patients in the context of metabolic comorbidities including diabetes is very important to ensure that treatment is tailored to meet the individual patient needs. Indeed, some pharmacological treatments may negatively affect metabolic comorbidities, and have important interactions with drugs that are commonly used to treat them. Non-pharmacological intervention such as diet and physical exercise could both improve the response to treatments for psoriasis and reduce the risk of diabetes and cardiovascular events.

show abstract

The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis

Cited by 468 publications

References 68 publications

Interleukin‐17‐producing γδ T (γδ17) cells in inflammatory diseases

Interleukin‐17‐producing γδ T (γδ17) cells in inflammatory diseases

New Possibilities of Pharmacotherapy for Immunoinflammatory Rheumatic Diseases: A Focus on Inhibitors of Interleukin-17

Systemic therapy of psoriasis in diabetic patients

Contact Info

Product

Resources

About